Cargando…
COVID-19 Rebound After Paxlovid Treatment: A Case Series and Review of Literature
Since the declaration of COVID-19 as a pandemic in 2020, several therapies have been developed to reduce symptoms of COVID-19 infection and prevent progression. Paxlovid is an antiviral that was authorized for emergency use in December 2021 for non-hospitalized symptomatic patients with COVID-19 to...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cureus
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308388/ https://www.ncbi.nlm.nih.gov/pubmed/35898366 http://dx.doi.org/10.7759/cureus.26239 |